• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

撤回：细胞周期蛋白依赖性激酶20（CDC20）可能作为基于生物标志物的风险评分系统用于预测肝细胞癌患者的预后。

Retracted: CDC20 May Serve as a Potential Biomarker-Based Risk Score System in Predicting the Prognosis of Patients with Hepatocellular Carcinoma.

作者信息

Longevity Oxidative Medicine And Cellular

出版信息

Oxid Med Cell Longev. 2023 Aug 2;2023:9806284. doi: 10.1155/2023/9806284. eCollection 2023.

DOI:10.1155/2023/9806284
PMID:37565158
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10412217/
Abstract

[This retracts the article DOI: 10.1155/2022/8421813.].

摘要

[本文撤回文章DOI: 10.1155/2022/8421813。]

相似文献

1
Retracted: CDC20 May Serve as a Potential Biomarker-Based Risk Score System in Predicting the Prognosis of Patients with Hepatocellular Carcinoma.撤回：细胞周期蛋白依赖性激酶20（CDC20）可能作为基于生物标志物的风险评分系统用于预测肝细胞癌患者的预后。
Oxid Med Cell Longev. 2023 Aug 2;2023:9806284. doi: 10.1155/2023/9806284. eCollection 2023.
2
CDC20 May Serve as a Potential Biomarker-Based Risk Score System in Predicting the Prognosis of Patients with Hepatocellular Carcinoma.CDK20 可作为预测肝细胞癌患者预后的潜在基于生物标志物的风险评分系统。
Oxid Med Cell Longev. 2022 Sep 19;2022:8421813. doi: 10.1155/2022/8421813. eCollection 2022.
3
Retracted: Identification of the HMMR Gene as a Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma Based on Integrated Bioinformatics Analysis.撤回：基于综合生物信息学分析鉴定HMMR基因作为肝细胞癌的诊断和预后生物标志物。
Evid Based Complement Alternat Med. 2023 Sep 27;2023:9819147. doi: 10.1155/2023/9819147. eCollection 2023.
4
A Novel Gene Signature Based on CDC20 and FCN3 for Prediction of Prognosis and Immune Features in Patients with Hepatocellular Carcinoma.基于 CDC20 和 FCN3 的新型基因标志物预测肝细胞癌患者的预后和免疫特征。
J Immunol Res. 2022 Mar 30;2022:9117205. doi: 10.1155/2022/9117205. eCollection 2022.
5
Retracted: Prediction of Prognosis and Molecular Mechanism of Ferroptosis in Hepatocellular Carcinoma Based on Bioinformatics Methods.撤回：基于生物信息学方法的肝细胞癌铁死亡预后预测及分子机制
Comput Math Methods Med. 2023 Jul 19;2023:9782763. doi: 10.1155/2023/9782763. eCollection 2023.
6
Retracted: G Protein Subunit Gamma 5 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma.撤回：G蛋白亚基γ5是一种预后生物标志物，与肝细胞癌中的免疫浸润相关。
Dis Markers. 2023 Jul 19;2023:9806936. doi: 10.1155/2023/9806936. eCollection 2023.
7
Retracted: Development of a Bile Acid-Related Gene Signature for Predicting Survival in Patients with Hepatocellular Carcinoma.撤回：用于预测肝细胞癌患者生存的胆汁酸相关基因特征的开发。
Comput Math Methods Med. 2023 Dec 6;2023:9865740. doi: 10.1155/2023/9865740. eCollection 2023.
8
The bioinformatics and experimental analysis of the novel roles of virus infection-associated gene CDC20 for prognosis and immune infiltration in hepatocellular carcinoma.病毒感染相关基因CDC20在肝细胞癌预后及免疫浸润中的新作用的生物信息学与实验分析
Aging (Albany NY). 2022 May 27;14(10):4513-4529. doi: 10.18632/aging.204093.
9
Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma.鉴定 CDC20 作为肝癌免疫浸润相关的预后生物标志物。
Invest New Drugs. 2021 Oct;39(5):1439-1453. doi: 10.1007/s10637-021-01126-1. Epub 2021 May 3.
10
Retracted: Analysis of the Performance of Gadoxetic Acid Disodium MRI in Predicting Microvascular Invasion of Hepatocellular Carcinoma.撤稿：钆塞酸二钠磁共振成像在预测肝细胞癌微血管侵犯中的性能分析。
Contrast Media Mol Imaging. 2023 Dec 13;2023:9761084. doi: 10.1155/2023/9761084. eCollection 2023.

本文引用的文献

1
CDC20 May Serve as a Potential Biomarker-Based Risk Score System in Predicting the Prognosis of Patients with Hepatocellular Carcinoma.CDK20 可作为预测肝细胞癌患者预后的潜在基于生物标志物的风险评分系统。
Oxid Med Cell Longev. 2022 Sep 19;2022:8421813. doi: 10.1155/2022/8421813. eCollection 2022.